These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33802327)

  • 1. Heightened Willingness toward Pneumococcal Vaccination in the Elderly Population in Shenzhen, China: A Cross-Sectional Study during the COVID-19 Pandemic.
    Zhang M; Chen H; Wu F; Li Q; Lin Q; Cao H; Zhou X; Gu Z; Chen Q
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33802327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with pneumococcal vaccination among an urban elderly population in China.
    Liu S; Xu E; Liu Y; Xu Y; Wang J; Du J; Zhang X; Che X; Gu W
    Hum Vaccin Immunother; 2014; 10(10):2994-9. PubMed ID: 25483646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Narii N; Kitamura T; Komukai S; Zha L; Komatsu M; Murata F; Maeda M; Kiyohara K; Sobue T; Fukuda H
    Vaccine; 2023 Mar; 41(13):2307-2313. PubMed ID: 36870877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
    Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with pneumococcal vaccination in elderly people: a cross-sectional study among elderly club members in Miyakonojo City, Japan.
    Sakamoto A; Chanyasanha C; Sujirarat D; Matsumoto N; Nakazato M
    BMC Public Health; 2018 Oct; 18(1):1172. PubMed ID: 30314498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ.
    Hayward S; Thompson LA; McEachern A
    J Patient Cent Res Rev; 2016; 3(2):111-115. PubMed ID: 27376105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study.
    Suzuki K; Kondo K; Washio M; Nakashima K; Kan S; Imai S; Yoshimura K; Ota C; Ohfuji S; Fukushima W; Hirota Y
    Hum Vaccin Immunother; 2019; 15(9):2171-2177. PubMed ID: 30785356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
    Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
    Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
    Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
    Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study.
    Chiou WY; Lee MS; Hung SK; Lin HY; Lo YC; Hsu FC; Tsai SJ; Li CY
    BMJ Open; 2018 May; 8(5):e019364. PubMed ID: 29769253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
    Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
    Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza Vaccination Coverage among Older Adults with Hypertension in Shenzhen, China: A Cross-Sectional Survey during the COVID-19 Pandemic.
    Li Q; Zhang M; Chen H; Wu F; Xian J; Zheng L; Liang M; Cao H; Zhou X; Gu Z; Lin Q; Chen Q
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral Intention to Receive a COVID-19 Vaccination Among Chinese Factory Workers: Cross-sectional Online Survey.
    Zhang KC; Fang Y; Cao H; Chen H; Hu T; Chen Y; Zhou X; Wang Z
    J Med Internet Res; 2021 Mar; 23(3):e24673. PubMed ID: 33646966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events.
    Ihara H; Kikuchi K; Taniguchi H; Fujita S; Tsuruta Y; Kato M; Mitsuishi Y; Tajima K; Kodama Y; Takahashi F; Takahashi K; Azuma N
    Vaccine; 2019 Oct; 37(43):6447-6453. PubMed ID: 31526624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population.
    Yunhua B; Peng B; Shuping L; Zheng Z
    Hum Vaccin Immunother; 2022 Nov; 18(6):2139123. PubMed ID: 36379017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between family physician's direct advice and pneumococcal vaccination intention and behavior among the elderly in Japan: a cross-sectional study.
    Higuchi M; Narumoto K; Goto T; Inoue M
    BMC Fam Pract; 2018 Sep; 19(1):153. PubMed ID: 30185157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.